Kapruvia

Difelikefalin, the active ingredient in Kapruvia, is a selective kappa‑opioid receptor agonist presented as an injectable solution for intravenous use. It is indicated for the treatment of pruritus associated with chronic kidney disease in patients receiving hemodialysis.

GNH USA supplies Kapruvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing quality‑assured products to healthcare institutions across multiple regions with regulatory compliance and reliable logistics.

Kapruvia (difelikefalin) is used to address itch symptoms within the chronic kidney disease (CKD) patient population.

- Pruritus associated with chronic kidney disease (CKD‑associated pruritus): reduces intensity of itch in hemodialysis patients. - Uremic pruritus in dialysis: improves patient‑reported quality of life by decreasing scratching episodes. - CKD‑related itching: provides an antipruritic effect when conventional therapies are insufficient.

Kapruvia may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness

Serious or Rare Side Effects: - Severe hypersensitivity reactions (e.g., anaphylaxis) - Hypotension - Respiratory depression

When prescribing Kapruvia, clinicians should consider several precautionary measures to ensure patient safety.

- Renal impairment: monitor response and adjust therapy as needed. - Hepatic impairment: use with caution, as metabolism may be altered. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Concomitant opioid therapy: risk of additive opioid effects; assess necessity. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kapruvia can interact with other medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Opioid agonists: additive opioid effects may increase risk of respiratory depression. - Central nervous system depressants: combined use may enhance sedation and dizziness. - Strong CYP3A4 inhibitors: may raise difelikefalin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure for additive hypotensive effect. - Antihistamines: may mask efficacy assessments of itch relief. - Antidepressants (e.g., SSRIs): observe for increased CNS effects.